Ovid Therapeutics (OVID) Total Current Liabilities (2016 - 2026)

Ovid Therapeutics' Total Current Liabilities history runs 11 years deep, the most recent figure standing at $15.7 million for Q1 2026.

• Quarterly Total Current Liabilities rose 69.21% year-over-year to $15.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.7 million (up 69.21% YoY) and the FY2025 annual result came in at $8.3 million, down 21.23% from the prior year.
• Total Current Liabilities was $15.7 million for Q1 2026 at Ovid Therapeutics, up from $8.3 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $15.7 million in Q1 2026 and bottomed at $6.7 million in Q1 2023.
• A 5-year average of $9.9 million and a median of $9.1 million in 2025 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities plunged 52.75% — and 2026, when it surged 69.21%.
• Ovid Therapeutics' Total Current Liabilities stood at $7.0 million in 2022, then soared by 64.1% to $11.5 million in 2023, then retreated by 8.29% to $10.5 million in 2024, then slipped by 21.23% to $8.3 million in 2025, then surged by 90.01% to $15.7 million in 2026.
• Business Quant data shows OVID's Total Current Liabilities at $15.7 million in Q1 2026, $8.3 million in Q4 2025, and $6.8 million in Q3 2025.